Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting session on the role of pazopanib in managing advanced renal cell carcinoma.
Kidney cancer or renal cancer is one of the common cancers that are found in both men and women and the burden of it is also increasing with time. Advanced RCC is stage 4 kidney cancer and it is highly difficult to cure.
Mostly, healthcare professionals focus on slowing down the progression of the disease or alleviating symptoms and improving the quality of life of the patients. However, ongoing research on advanced RCC has come up with new treatments with Food and Drug Administration (FDA) approval.
Pazopanib is an anti-cancer medication that can block tumor cell growth in several ways. It targets several proteins primarily, tyrosine kinases which are present on the surface of cancer cells. Moreover, several of these targeted cells are also involved in angiogenesis (making of blood vessels).
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
An ancient signaling pathway and 20 years of research offer hope for rare cancer
2.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
3.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
Prostate cancer detection with PET CT and PET MRI is comparable.
1.
Cutting-Edge Cancer Care: The Precision Revolution in Surgical Oncology
2.
Decoding the Padua Score to Prevent Blood Clots in High-Risk Patients
3.
Exploring The Causes and Consequences of Low Transferrin Saturation
4.
Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation
5.
Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation